Hepatocellular carcinoma is one of the major cancer killers. It affects patients with chronic liver disease who have established cirrhosis, and currently is the most frequent cause of death in these patients. The main risk factors for its development are hepatitis B and C virus infection, alcoholism and aflatoxin intake. If acquistion of risk factors is not prevented and cirrhosis is established, the sole option to improve survival is to detect the tumor at an early stage when effective therapy may be indicated. Early detection plans should be based on hepatic ultrasonography every 6 months, whereas determination of tumor markers is not efficient. Upon detection of a hepatic nodule, there is a need to establish unequivocal diagnosis, either through biopsy or through the application of non-invasive criteria based on the specific radiology appearance of the tumor: fast arterial uptake of contrast followed by venous washout. Effective treatment for liver cancer includes surgical resection, liver transplantation and percutaneous ablation. These options provide a high rate of complete responses and are assumed to improve survival that should exceed 50% at 5 years. If the tumor is diagnosed at an advanced stage, the sole option that improves survival is transarterial chemoembolization. Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression.
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1 BCLC Group, Liver Unit, IDIBAPS, Digestive Disease Institute, Hospital Clínic, University of Barcelona, Catalonia, Spain and 2 BCLC Group, Radiology Department, IDIBAPS, Hospital Clínic, University of Barcelona, Catalonia, Spain Hepatocellular carcinoma is one of the major cancer killers. It affects patients with chronic liver disease who have established cirrhosis, and currently is the most frequent cause of death in these patients. The main risk factors for its development are hepatitis B and C virus infection, alcoholism and aflatoxin intake. If acquistion of risk factors is not prevented and cirrhosis is established, the sole option to improve survival is to detect the tumor at an early stage when effective therapy may be indicated. Early detection plans should be based on hepatic ultrasonography every 6 months, whereas determination of tumor markers is not efficient. Upon detection of a hepatic nodule, there is a need to establish unequivocal diagnosis, either through biopsy or through the application of non-invasive criteria based on the specific radiology appearance of the tumor: fast arterial uptake of contrast followed by venous washout. Effective treatment for liver cancer includes surgical resection, liver transplantation and percutaneous ablation. These options provide a high rate of complete responses and are assumed to improve survival that should exceed 50% at 5 years. If the tumor is diagnosed at an advanced stage, the sole option that improves survival is transarterial chemoembolization. Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression. Oncogene (2006 Oncogene ( ) 25, 3848-3856. doi:10.1038 Keywords: hepatocellular carcinoma; early detection; diagnosis; treatment Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world and third most common cause of cancer-related mortality. Current data indicate that it induces more than 500 000 deaths/year (GRETCH, 2004; Parkin et al., 2005) . There are major differences in the incidence rates according to geographical areas, this heterogeneity being due to the different prevalence of the several oncogenic factors (hepatitis B and C viruses (HBV and HCV) , alcoholism, aflatoxin intake) in the different populations (Bosch et al., 2004) . Nevertheless, a common trait in all areas is that in most HCC cases, cirrhosis underlies the neoplasm . This relationship between oncogenicity and the process of chronic inflammation associated with hepatocyte necrosis and regeneration, ultimately resulting in the development of collagen deposition and cirrhosis, provides both an insight into the potential mechanisms leading to liver cancer and an identification of the population at risk. This is of paramount importance for the cost efficiency of screening plans aiming to detect HCC at an early stage when effective therapy might be successfully applied (Bruix and Sherman, 2005) . In that sense, it has to be stressed that diagnosis and management of HCC has sharply changed during the last two decades. Until the development of ultrasound (US), most of the patients were diagnosed at a symptomatic stage, when tumor stage was already advanced and hence, treatment was unfeasible. Not unexpectedly, life expectancy after diagnosis was short, and most patients died within the first year of follow-up. As said, this grim scenario is no longer true. Ultrasound allows early HCC detection, and dynamic imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) permit an accurate assessment of tumor burden . This tumor staging coupled with proper evaluation of the functional hepatic reserve of the underlying cirrhotic liver allows us to decide if the patients can benefit from one of the several effective therapies that are currently available (surgical resection, liver transplantation, percutaneous ablation, chemoembolization) (Bruix and Sherman, 2005) . If this is not the case, the optimal best approach is to consider the patients for entering a research investigation to test the several new agents that have recently reached the transition from the bench to the bedside.
In the present chapter, we will review the strategy that has to be applied to establish the diagnosis of HCC and the decision-making model to indicate the treatment to be offered. While exposing the current state-of-the-art knowledge in these areas, we will simultaneously point out the most recent developments and the aspects that need more active research in the near future.
Diagnostic approach
As previously mentioned, decades ago, the diagnosis of HCC was almost always made at a symptomatic stage. Patients complained of abdominal pain, malaise and weight loss, and usually exhibited symptoms of advanced liver failure, such as jaundice, ascites and encephalopathy. Physical examination evidenced a tumoral liver. Alpha-fetoprotein (AFP) was frequently increased, and the diagnosis was easily established. Biopsy of the mass could even be made by manual guidance, and pathological examination of the sampled tissue disclosed poorly differentiated malignant hepatocytes. This grim scenario is still present in undeveloped countries with less than optimal health care, but in developed countries, the diagnostic process is completely different. The improvement in health management has allowed the detection and diagnosis of patients with chronic liver disease, and those who have developed cirrhosis are entered into early detection plans (Bruix and Sherman, 2005) . This intervention is not initiated before the establishment of cirrhosis, as the incidence of HCC in non-cirrhotic chronic hepatitis is low and, thus, cost efficacy according to conventional criteria (longevity should be increased by at least 100 days (Naimark et al., 1994) , and each year of life gained should cost less than $50 000 (Laupacis et al., 1992) would never be reached (Bruix and Sherman, 2005) . There is a single randomized controlled trial (RCT) assessing the benefits of HCC screening, and it has shown positive results in Chinese HBV patients (Zhang et al., 2004) . However, no such investigation is available in the West or in HCV patients. An RCT is currently seen as unfeasible because awareness of the HCC risk and the benefits of early detection would prevent any individual to be randomized to the control group (Bruix and Sherman, 2005) . Cohort studies and cost-effectiveness analysis homogeneously suggest that screening plans are effective if patients entered into screening would be treated if diagnosed with HCC (Bolondi, 2003) . This apparently irrelevant condition is critical. The idea behind HCC screening is to detect tumors at early stages of development when treatment would decrease mortality from the disease. If screening just results in earlier detection but no effective therapy is available or feasible, the effort will have no real impact.
According to these comments, it is recommended that cirrhotics due to viral infection, alcoholism, genetic hemochromatosis and primary biliary cirrhosis should be entered into screening programs (Bruix and Sherman, 2005) . Cirrhotic patients due to viral hepatitis who are co-infected with HIV should also be screened. Absence of incidence data prevent us from knowing if patients with alpha 1-antitrypsin deficiency, Wilson's disease, non-alcoholic steatohepatitis or autoimmune hepatitis are at enough of a risk for HCC to warrant surveillance (Bruix and Sherman, 2005) . Finally, patients enlisted for liver transplantation should be screened to detect small tumors that might require therapy and to identify patients who develop cancers that exceed transplantation guidelines.
Screening assays
Screening assays for HCC are either serological (tumor markers, e.g., AFP) or radiological (US, CT or MRI).
Unfortunately, tumor markers lack enough sensitivity and specificity to be used for early detection (Marrero and Lok, 2004) . The most specific tumor marker is AFP, but several studies have shown that, even when tested as diagnostic tool, its sensitivity and specificity is reduced (Sherman, 2001; Bruix and Sherman, 2005) . A cutoff value of 20 ng/ml appears to offer the optimal balance between sensitivity and specificity. Sensitivity, however, is only 60%, and this figure is far lower if using a conventional cutoff of 200 ng/ml (Trevisani et al., 2001) or if the analysis is restricted to small early HCC. Even if AFP is ineffective for screening and diagnosis, it is a powerful tool to identify patients at higher risk for HCC development (Bruix et al., 2001) . Other serological assays, including des-gamma-carboxy prothrombin (DGCP, or Prothrombin Induced by Vitamin K Absence II, PIVKA II) (Suehiro et al., 1994; Izuno et al., 1995; Koike et al., 2001; Marrero et al., 2003) , the ratio of glycosylated AFP (L3 fraction) to total AFP (Kumada et al., 1999) , alpha fucosidase (Ishizuka et al., 1999) and glypican 3 (Capurro et al., 2003) are either defective or remain to be adequately investigated. Proteomic investigations and gene microarray studies should be able to identify new substances to be used for screening and diagnosis. Some recent studies support this hope (Paradis et al., 2005) . However, until properly tested in large cohorts and adequately validated, screening and diagnosis will still have to be based on imaging techniques.
Currently, the optimal tool for screening is ultrasonography (US). Lesions on US may appear hyperechoic, hypoechoic or as 'target lesions', none of which is specific (Bruix and Sherman, 2005) . Any mass detected on US in a cirrhotic liver is suspicious of HCC, especially if it exceeds 1 cm ( Figure 1 ). Ultrasound sensitivity for screening ranges between 65 and 80% and has a specificity of >90% (Bruix and Sherman, 2005) . Figure 1 Hepatic ultrasound showing a hypoechoic nodule measuring less than 20 mm in diameter within a cirrhotic liver. It corresponded to an early hepatocellular carcinoma that was diagnosed by fine needle biopsy as imaging techniques (dynamic computed tomography and magnetic resonance imaging) did not evidence the specific pattern consisting of intense contrast uptake during the arterial phase and washout during the delayed/venous phase.
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Based on the few data about tumor volume doubling time, the ideal screening interval has been proposed to be 6 months.
Diagnostic criteria
Upon US detection of a hepatic nodule either within a surveillance plan or within the standard evaluation of patients with suspected or known liver disease, the next clinical step is to characterize the nodule and establish its diagnosis. Dynamic imaging techniques are critical for this purpose, as they take advantage of the characteristic vascular profile of HCC. This evolves from being exclusively based on venous portal branches in dysplastic nodules to becoming almost exclusively arterial upon transition into established HCC. According to this vascular pattern, HCC nodules are recognized by an intense contrast uptake during the arterial phase of the imaging technique (immediately after contrast injection), whereas the contrast is washed away during the delayed/venous phase . This pattern has an almost 100% specificity if observed in a nodule >1 cm arising within a cirrhotic liver and, thus, is used for the non-invasive diagnostic criteria of the neoplasm (Bruix and Sherman, 2005) . The dynamic imaging techniques that can be used for diagnosis are contrast-enhanced US, CT and MRI. However, some HCC may not exhibit a typical pattern and display a less intense arterial uptake or a lack of venous washout, and in this instance the diagnosis should be based on biopsy and pathological examination (Bruix and Sherman, 2005) . According to these data, the recent AASLD guidelines proposed the diagnostic strategy depicted in Figure 2 and Table 1 (Bruix and Sherman, 2005) . In brief, minute nodules o1 cm in diameter are proposed Mass on surveillance ultrasound in a cirrhotic liver for careful follow-up, as current diagnostic techniques are not accurate enough to confidently establish the diagnosis. Nodules between 1 and 2 cm should be characterized by imaging techniques. If two of them show coincidental and specific dynamic pattern, the HCC diagnosis can be established. Finally, nodules >2 cm in size that exhibit a characteristic dynamic profile can be diagnosed as HCC by using a single imaging technique. If the vascular pattern is not specific for HCC, a biopsy should be taken to establish the diagnosis, which may not in all instances correspond to HCC even though this may be the final diagnosis in the majority of the cases (Bruix and Sherman, 2005) . It has to be emphasized that biopsy does not have a 100% sensitivity. Hence, a negative result does not rule out malignancy, and a repeat biopsy may be requested (Bruix et al., 2001) .
Prognosis prediction and staging
The outcome of patients diagnosed with HCC is influenced by the extent of tumor burden, liver function, physical status and the treatment efficiency (Sala et al., 2005) . Unidimensional systems that take into account just one of these factors, such as the Child-Pugh classification, tumor-node-metastasis staging or Karnofsky score, lack proper predictive power. There are several proposals joining liver function and tumor extent that are able to stratify patients according to expected survival, but none of them has been properly validated. The sole staging system that links staging with treatment indication and life expectancy estimation is the Barcelona Clinic Liver Cancer (BCLC) proposal (Figure 3 ) . This is the result of various randomized clinical trials and cohort studies of disease stages and therapeutic modalities and stratifies patients into different categories according to tumor burden, liver function and physical status. A unique group is formed by tumors classified as very early HCC. Currently, these initial lesions can only be diagnosed after surgery, as they correspond to well-differentiated HCC o2 cm in size that have not invaded vessels or formed satellite lesions. They are usually hypovascular and correspond to the so-called carcinoma in situ entity (Takayama et al., 1998 Diagnosis and therapy of HCC J Bruix et al status o2) and/or vascular invasion or extrahepatic spread. No treatment has proven a survival benefit, and they are candidates for therapeutic trials with novel agents. End-stage patients have extensive tumor involvement and depressed physical status (bedridden >50% of the day) and/or liver function (Child-Pugh C) and a life expectancy of o3 months. The BCLC system has become a very useful clinical decision tool, and its prognostic power has been recently validated in US (Marrero et al., 2005) and Italian (Grieco et al., 2005) cohorts.
Current treatment
Whereas years ago, HCC diagnosis was almost always established at advanced stage and available options had no applicability or efficacy, the current status is markedly different. As more patients are diagnosed before hepatic decompensation and the emergence of cancer-related symptoms, it is possible to halt and even cure HCC. For early-stage disease where a cure is possible, current treatment options include surgical resection, transplantation and percutaneous ablation (Bruix and Sherman, 2005) . Transarterial chemoembolization (TACE) is the only non-curative therapy that has been shown to increase survival, whereas arterial embolization without chemotherapy or internal radiation has some anticancer activity but does not increase survival . Systemic chemotherapy with different agents is marginally effective against HCC but severely toxic and unassociated with increased survival Bruix and Sherman, 2005) . Agents such as tamoxifen , antiandrogens (Grimaldi et al., 1998) and octreotide (Yuen et al., 2002) are completely ineffective.
Surgical resection
For years, surgical resection has been considered the sole potentially curative option, but currently it competes with transplantation and percutaneous ablation. There are no RCTs comparing the respective value of each and, thus, no evidence-based data to establish which should be the first-line option. Resection is usually indicated in patients with solitary HCC and preserved liver function. The remaining hepatic reserve should suffice to support adequate liver function. Obviously, this poses no difficulty in the few patients in whom HCC arises within a normal liver. By contrast, evaluation of liver function in patients with cirrhosis is more subtle. Japanese groups rely on Child-Pugh classification coupled with an ICG retention test (Torzilli et al., 1999) . In Europe and the US, the best results are obtained in Child-Pugh A patients with the absence of clinically relevant portal hypertension, as reflected by a hepatic venous pressure gradient o10 mm Hg (Bruix et al., 1996) . Survival of properly selected candidates exceeds 70% at 5 years, and this figure is sharply reduced if strict selection is not in place (Llovet et al., 1999b (Llovet et al., , 2005 . Despite the careful staging of patients by dynamic techniques aiming to identify patients with solitary HCC without satellites or vascular invasion, there will always be 10-15% of understaging, as has been demonstrated both in resection and transplant studies (Burrel et al., 2003; . More than 80% of the patients will present disease recurrence during follow-up (Llovet et al., 2005) . In the majority of the patients, the recurrence will be owing to disseminated tumor sites, whereas in the rest it will correspond to metachronic tumors arising in the oncogenic cirrhotic liver. The first type may be predicted by the detection of satellites or microscopic vascular invasion and will appear within the first 2 years of follow-up . The second category is related to the degree of liver insult with repeated oncogenic events and will more frequently appear later during follow-up . Several strategies have been proposed to diminish recurrence risk. Preoperative chemoembolization and chemotherapy have no efficacy. Promising results have been reported by adaptive immunotherapy (Takayama et al., 2000) and selective radiotherapy (Lau et al., 1999) , which ideally would act on unrecognized disseminated tumor nests. Similarly, retinoid administration (Muto et al., 1996) and interferon therapy (Shiratori et al., 2003) have also been suggested to be active in preventing metachronic HCC. Unfortunately, none of the available data suffice to incorporate any of these options in conventional clinical practice (Bruix and Sherman, 2005) . As liver transplantation offers less risk of recurrence and the same chance of survival, we have recently proposed that resected patients with a high risk of recurrence should be offered transplantation even in the absence of recurrence (Sala et al., 2004a) . Recurrence in these cases is often multifocal, and salvage transplantation is not feasible. On the contrary, those patients who present low risk could avoid this more invasive option and be carefully evaluated for the development of metachronic HCC.
Liver transplantation
Whereas resection should be restricted to patients with well-preserved liver function, liver transplantation is a suitable treatment option for patients with liver functional impairment (Child-Pugh B-C) and in that setting also reverses the poor outcome related to advanced liver disease (Llovet et al., 2005) . In almost all groups, the selection policy follows the so-called Milan criteria (Mazzaferro et al., 1996) , which has been validated by experiences in France (Bismuth et al., 1993) , Spain (Llovet et al., 1998) and Germany (Jonas et al., 2001) . In brief, selection includes patients with a single HCC p5 cm or up to three nodules o3 cm each. Under such conditions, the 5-year survival rate is >70%. Although debate continues as to whether these criteria can be expanded , data supporting such a change are limited and do not, furthermore, define what the new cutoffs should be.
As the demand for livers outstrips the supply, potential recipients must wait to be transplanted. During the waiting period, the tumor could grow into the vascular supply or beyond the liver capsule, both of which are major contraindications for transplantation. If the waiting list is as long as 12 months, up to 25% of patients may be excluded owing to tumor advancement, an unfortunate event that translates to 60% survival based on intention-to-treat (Llovet et al., 1999b) . Efforts to reduce the dropout rate include increasing the number of liver donations, establishing an effective priority policy and applying treatment to delay tumor progression while waiting for a liver. Health campaigns should result in increased liver donation rates worldwide. Priority policies have been developed in several countries, but there are no good criteria to provide a fair distribution of livers among the different categories of disease candidates to transplant (malignant vs nonmalignant, cirrhosis vs metabolic vs cholestatic). Finally, giving excessive priority to too advanced or too sick patients may hamper the long-term results because of higher rates of recurrence, death or both. In the US, HCC patients were initially given extra points to match the risk of death in end-stage cirrhosis: 24 for solitary HCC o2 cm and 29 for solitary HCC 2-5 cm or three nodules o3 cm each (Freeman et al., 2004) . However, these numbers gave HCC patients too high a priority (Sharma et al., 2004) , and they were subsequently lowered several times and are currently 0 and 22, respectively (Freeman et al., 2004) . Results of this adjustment are eagerly awaited.
Most groups treat HCC upon listing but there is no robust evidence supporting a benefit of therapy. Transarterial chemoembolization reduces tumor burden and delays progression (Bruix et al., 2004; Majno et al., 2005) , but it cannot be applied in decompensated patients. Ablation of small tumors by percutaneous ethanol injection (PEI) or radiofrequency is cost effective if the expected waiting time is >6 months (Llovet et al., 2002a) , although it also carries a risk of tumor seeding, in particular if the tumor is poorly differentiated and/or located in the liver periphery Livraghi et al., 2003) .
Overall, the best method for decreasing waiting-list dropouts is to increase the number of available livers. Various strategies have been examined, the most promising among them being live donation. Over 4000 living donor liver transplants using the right hepatic lobe have been performed worldwide, and early-to intermediate-term results from Asia (Kawasaki, 2002; Steinmuller et al., 2002; Gondolesi et al., 2004) and Japan (Todo and Furukawa, 2004) indicate that its performance is similar to cadaveric transplant and should be considered an option if the waiting time exceeds 7 months. However, there are some data suggesting that recurrence of HCV infection is more severe in patients receiving live donation (GarciaRetortillo et al., 2004) , and this may force a reduction in the initial enthusiasm toward this treatment modality.
Percutaneous ablation
This is the last option that can provide complete elimination of the tumor if it is of reduced size. The recurrence rate after successful ablation is the same as after resection, and survival may also be very similar, fueling a debate over the extent to which surgical resection should be preferred to ablation. Again, no RCTs are available, and no conclusive answer can be given. However, the similarity in efficacy may be restricted solely to solitary tumors o2 cm in size. In larger tumors, the risk of incomplete ablation by any of the available ablation techniques suggests that if resection is feasible, it is more reliable and thus may be more beneficial. In small tumors, resection will also inform about the risk of recurrence and, as previously commented, allow the enlistment for transplantation based on this risk (Sala et al., 2004a) . Hence, we still prefer resection over ablation as the first-line treatment for HCC. Ablation has been proposed to be effective in patients with single HCCs o5 cm or up to three nodules o3 cm. However, the best results are obtained in solitary tumors o2 cm (Sala et al., 2004b; Tateishi et al., 2005) . Chemicals (ethanol, acetic acid or boiling saline) or extreme temperatures (radiofrequency, microwave, laser or cryotherapy), typically administered under US guidance, are used to destroy tumor cells. The absence of contrast uptake on CT assessed 1 month post-therapy is indicative of tumor death (Bruix et al., 2001) .
Percutaneous ethanol injection has been almost the sole tumor ablation technique for years. Ninety-five percent absolute ethanol is injected in and around the tumor in order to induce protein denaturation and small vessel thrombosis. The technique is inexpensive, and complications are rare (Livraghi et al., 1995; Di Stasi et al., 1997) . Death due to treatment occurs in 0.009-0.1% of cases (Beaugrand et al., 2005) . It is effective in 90-100% of HCCs o2 cm, 70% 2-3 cm in diameter and 50% between 3 and 5 cm (Sala et al., 2004b) . In patients with preserved liver function (Child-Pugh A) and tumors o3 cm, 5-year survival rates may be as high as 50%. The main drawbacks to PEI are that it requires several days of repeated injections (four sessions, typically, to achieve complete necrosis) and its success in tumors >3 cm is uncommon.
Radiofrequency ablation (RFA) has been shown to circumvent most of these issues. It uses an alternating electric current, delivered via electrode, to heat and destroy tumor cells. In tumors o2 cm, it is as efficacious as PEI and requires fewer sessions (Livraghi et al., 1999; Lencioni et al., 2003) ; in tumors >2 cm, it is more efficacious than PEI (Livraghi et al., 1999; Lencioni et al., 2003; Lin et al., 2004; Shiina et al., 2005) . One session of RFA can achieve complete necrosis in 88-98% of tumors o3 cm and 80-90% of those 3-5 cm in diameter, and recent RCTs suggest that this higher efficacy translates in an improvement in survival as compared to ethanol injection (Lin et al., 2004; Shiina et al., 2005) . Radiofrequency ablation, however, is associated with more adverse effects. Pleural effusion and/or hemoperitoneum occur in almost 10% of treated patients, and the mortality rate for the procedure is 0-0.3% (Livraghi et al., 2003; Giorgio et al., 2005; Tateishi et al., 2005) . Radiofrequency ablation of tumors that are poorly differentiated or in a subcapsular location imports a higher risk of peritoneal seeding Livraghi et al., 2003) and is therefore contraindicated. Radiofrequency ablation is also contraindicated for tumors adjacent to the gastrointestinal tract, large bile ducts or large blood vessels.
In addition to RFA, other techniques of thermal ablation include microwave, laser and cryoablation. Microwave ablation, used chiefly in China and Japan, requires less time than RFA but more sessions (Shibata et al., 2002) and is best at treating small HCCs. Laser ablation takes longer to perform, and its risks are similar to those associated with RFA (Beaugrand et al., 2005) . Cryoablation (rapid freezing to generate intratumoral ice crystals) portends greater and different risks than RFA, such as liver cracking and the so-called cryoshock phenomenon.
Transcatheter arterial embolization/transarterial chemoembolization Early HCC is mostly vascularized by the portal vein; as the tumor expands, the blood supply becomes progressively more arterial. This phenomenon provides not only the basis for the radiological characteristics used to diagnose HCC but also the rationale for therapeutic hepatic artery obstruction of intermediate-stage tumors via transcatheter arterial embolization (TAE) and TACE (Bruix et al., 2004) . In TACE, a solution of chemotherapy (frequently doxorubicin or cisplatin) suspended in lipiodol, an oily contrast medium selectively retained within the tumor, is injected into the smallest branch of the hepatic artery directly supplying the lesion (Bruix et al., 2004) . This is then followed by the obstruction of the feeding arteries by an embolizing agent. In the case of TAE, the embolizing agent is the only agent administered. A solution of 1-mm Gelfoam cubes is most common, but polyvinyl alcohol, alcohol, starch microspheres, metallic coils (Bruix et al., 1994) and autologous blood clots (Bruix et al., 2004) have also been used.
Transcatheter arterial embolization and TACE are indicated for patients with non-surgical HCC who are ineligible for percutaneous ablation yet free of vascular invasion or extrahepatic tumor growth. Contraindications include low-to-no portal blood flow, which can lead to hepatic infarct, and advanced liver disease (Child-Pugh B-C), which portends a high risk of liver failure and death. Transcatheter arterial embolization and TACE provoke extensive necrosis in >50% of tumors (Bruix et al., 2004) , evidenced by a decline in tumor markers and tumor burden as seen on imaging (Bruix et al., 2001) . Even though necrosis may appear macroscopically complete, histological examination reveals viable neoplastic cells, which are responsible for the high rate of post-treatment recurrence. Additional treatments are administered either at specified intervals or as needed, no data plainly favoring either strategy (Bruix et al., 2004) .
The impact on survival was not evidenced until recently, when two RCTs from Barcelona (Llovet et al., 2002b) and Hong Kong provided positive results with TACE. This permitted a positive cumulative meta-analysis , and currently TACE should be considered standard of care for patients with HCC diagnosed at an intermediate stage. Interestingly, the observation of a positive response to treatment is associated with increased survival and delayed tumor progression. Hence, current research now targets agents that could enhance and maintain the therapeutic response without simultaneously increasing the side effects.
Treatment algorithm
As previously mentioned, the BCLC staging system (Llovet et al., 1999a Bruix and Llovet, 2002 ) not only stratifies HCC patients according to disease stage but also indicates which treatment, if any, offers each individual the best chance for survival (Figure 3 ).
For very early (Stage 0) or early-stage patients with a single tumor (ideally o5 cm in diameter) (Stage A) and neither portal hypertension nor elevated bilirubin, the treatment of choice is surgical resection.
For early-stage patients (Stage A) with either a single nodule o5 cm or three nodules o3 cm each, plus enough liver functional damage to rule out resection, the treatment of choice is transplantation. If surgery is not feasible, percutaneous ablation is currently the selected approach.
For patients with asymptomatic liver disease (ChildPugh A) and multinodular tumors without extrahepatic spread or vascular invasion (Stage B), the treatment of choice is TACE.
These are the only treatment options for HCC that have any impact on survival. Patients who are of an advanced stage due to liver failure, vascular or extrahepatic involvement, or mildly impaired physical status can be enrolled in RCTs testing novel agents vs placebo or given supportive care, whereas terminal patients should be treated symptomatically to avoid unnecessary suffering.
Future perspectives
It has to be acknowledged that, until now, the therapeutic armamentarium to battle against liver cancer has been moderately effective and can be mostly classified as mechanical. Major effort has been put forth to achieve early diagnosis and refine treatment selection. At the same time, proper evaluation of several options has shown their lack of benefit, and, accordingly, treatment of liver cancer is a major area open for investigation. Current research is trying to dissect the mechanisms through which agents that induce chronic liver disease result in associated genetic damage leading to cancer development. Furthermore, upon cancer generation, there are a large number of pathways leading to the uncontrolled proliferation, invasion and dissemination that ultimately result in the death of the patient. Obviously, identification of all these molecular governors of biological events should provide a better and more rational prevention and treatment of cancer, including HCC. Antiangiogenic agents, triggers of apoptosis and blockers of proliferation signaling are currently in human testing, and hopefully sometime in the near future, the treatment strategy for cancer will take a completely different approach.
